China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Large Increase in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 4,613,535 shares, a growth of 20,385.5% from the July 15th total of 22,521 shares. Approximately 12.6% of the company’s stock are short sold. Based on an average trading volume of 121,753,983 shares, the days-to-cover ratio is currently 0.0 days.

China SXT Pharmaceuticals Trading Down 2.2%

Shares of China SXT Pharmaceuticals stock opened at $3.51 on Wednesday. The firm’s 50 day simple moving average is $132.49 and its two-hundred day simple moving average is $188.85. China SXT Pharmaceuticals has a 12-month low of $3.15 and a 12-month high of $83,758.80. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.76 and a current ratio of 7.94.

China SXT Pharmaceuticals (NASDAQ:SXTC) last announced its quarterly earnings data on Wednesday, July 1st. The company reported ($5.60) earnings per share for the quarter. The firm had revenue of $0.26 million for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of China SXT Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, China SXT Pharmaceuticals currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd acquired a new stake in shares of China SXT Pharmaceuticals during the fourth quarter worth about $36,000. Virtu Financial LLC raised its position in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after buying an additional 15,013 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in China SXT Pharmaceuticals during the 3rd quarter worth approximately $78,000. 5.02% of the stock is currently owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.